Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Durect has reported positive results from a Phase IIa clinical trial for Eladur, the company's proprietary investigational transdermal pain patch.
Subscribe to our email newsletter
In this study of patients suffering from post-herpetic neuralgia, Eladur showed improved pain control versus placebo during the three-day continuous treatment period. In addition, Eladur appeared well tolerated overall, and patients treated with Eladur and placebo exhibited similar safety profiles.
This Phase IIa study was a randomized, multi-center, double-blind, placebo-controlled, two-way cross-over study of 60 patients suffering from post-herpetic neuralgia (post-shingles pain or PHN). The objectives of the study were to assess the safety as well as the magnitude, duration and characteristics of analgesic activity of Eladur. Durect anticipates that detailed results will be submitted in May 2008.
James Brown, president and CEO of Durect, said: “To our knowledge, this is the first topical local anesthetic formulation that supports a full three days of pain control from a single application.”